instruction stringlengths 634 1.17k | output stringlengths 581 950 |
|---|---|
SUBJECT: Integrated feedback regarding Product A
BODY:
Dear adverse event reporting center,
As part of our procurement cycle for Q3, we are reassessing supplier agreements for key therapeutic categories.
We need the global pharmacovigilance contact details and the medical information request portal for Product A.
Th... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "98%"}, "Analysis": "The email describes that the patient noticed yellowing of sclera and skin suggestive of hepatic involvement after 10 days which is an Adverse Event, requests specific clinical info... |
SUBJECT: Unexpected reaction linked to Product A
BODY:
Dear medical information,
Our quality team flagged that a tablet was detected to be split into 2 unequal fragments inside an intact blister cavity. Our quality officer requests a certificate of analysis for the specific batch in question.
The patient is a 75 year... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "96%"}, "Analysis": "The email describes that the patient noticed yellowing of sclera and skin suggestive of hepatic involvement after 10 days which is an Adverse Event, requests cli... |
SUBJECT: Healthcare provider memo on Product A
BODY:
Hello,
As part of our procurement cycle for Q3, we are reassessing supplier agreements for key therapeutic categories.
Can you confirm the lead time and minimum order quantity for direct-to-hospital shipments of Product A?
The patient is a 47 year old male with ma... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "91%"}, "Analysis": "The email describes that the patient complained of severe abdominal cramping and diarrhea for 3 consecutive days which is an Adverse Event, requests clinical inf... |
SUBJECT: Pricing inquiry and safety signal for Product A
BODY:
Dear product team,
Our pharmacy flagged that the syringe plunger was stuck and could not be depressed smoothly, suggesting a manufacturing defect. The defective units have been isolated and are available for return analysis.
Our health system serves appro... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "95%"}, "Analysis": "The email requests specific clinical information by asking Is there any guidance on dose modification for patients with hepatic impairment? which is Medical Information, report... |
SUBJECT: Product quality and adverse experience with Product A
BODY:
Dear regulatory affairs,
The subject is a 38 year old female with rheumatoid arthritis. She noticed yellowing of sclera and skin suggestive of hepatic involvement after 10 days. The patient was transferred to a higher level of care for continuous mon... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "90%"}, "Analysis": "The email describes that the patient noticed yellowing of sclera and skin suggestive of hepatic involvement after 10 days which is an Adverse Event, requests cli... |
SUBJECT: Labeling error and clinical query about Product A
BODY:
Dear post-market surveillance,
The patient is a 41 year old female with asthma and seasonal allergies. She had an episode of syncope approximately 6 hours post-dose. We immediately discontinued the drug and initiated supportive care.
To guide our ongoin... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "95%"}, "Analysis": "The email describes that the patient had an episode of syncope approximately 6 hours post-dose which is an Adverse Event, requests specific clinical information by asking Can you s... |
SUBJECT: Healthcare provider memo on Product A
BODY:
Dear global safety,
The individual is a 67 year old female with breast cancer on adjuvant therapy. She was started on Product A. During therapy she suffered profound fatigue and muscle weakness after 6 days of treatment. The clinical team documented the event and sc... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "95%"}, "Analysis": "The email describes that the patient experienced profound fatigue and muscle weakness after 6 days of treatment which is an Adverse Event, requests clinical information... |
SUBJECT: Combined quality and clinical report for Product A
BODY:
Dear clinical and supply chain team,
The chief financial officer has asked for a competitor price comparison across all biologic agents.
Our group purchasing organization is aggregating demand across 40 hospitals and needs tiered pricing for Product A.... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "89%"}, "Analysis": "The email describes that the patient reported visual disturbances including blurred vision and photophobia after 3 doses which is an Adverse Event, requests clin... |
SUBJECT: Supply and experience review of Product A
BODY:
Dear customer support,
The patient is a 38 year old female with rheumatoid arthritis. She was started on Product A. Within days of starting she reported dyspnea and chest tightness within 30 minutes of ingestion. The patient received IV glucagon and dextrose in ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "95%"}, "Analysis": "The email describes that the patient reported dyspnea and chest tightness within 30 minutes of ingestion which is an Adverse Event, requests clinical information by ask... |
SUBJECT: Follow-up needed for Product A
BODY:
Dear medical and commercial affairs,
The regional payer consortium has requested additional data to finalize coverage policy.
Who should we contact from your team for business collaboration or partnership opportunities related to Product A? Are there any institutional sup... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "91%"}, "Analysis": "The email reports that a vial arrived with a cracked neck, causing leakage of approximately 2 ml of solution related to Product A which is a Product Complaint, describes that the pat... |
SUBJECT: Product quality and adverse experience with Product A
BODY:
Dear global safety,
The patient is a 55 year old female with a history of migraine. She experienced a sharp drop in platelet count observed on day 7 lab work. The patient received IV glucagon and dextrose in the emergency department.
To guide our on... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "89%"}, "Analysis": "The email describes that the patient experienced a sharp drop in platelet count found on day 7 lab work which is an Adverse Event, requests specific clinical information by asking ... |
SUBJECT: Pricing inquiry and safety signal for Product A
BODY:
Dear patient safety and market access team,
Our integrated delivery network is standardizing procurement across 12 facilities and needs a master service agreement.
We are evaluating Product A for our hospital formulary and need the health technology asses... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "93%"}, "Analysis": "The email describes that the patient developed a widespread erythematous rash within 48 hours of the first dose which is an Adverse Event, requests clinical info... |
SUBJECT: Pricing inquiry and safety signal for Product A
BODY:
Dear product team,
The patient is a 78 year old female on chronic warfarin therapy. She was administered Product A from a lot where the insulin cartridge contained visible fibrils or precipitate that should not have been present. The incident has been docu... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "94%"}, "Analysis": "The email describes that the patient complained of severe abdominal cramping and diarrhea for 3 consecutive days which is an Adverse Event, requests clinical informatio... |
SUBJECT: Product quality and adverse experience with Product A
BODY:
Hello,
The subject is a 26 year old female with epilepsy. She suffered from persistent headaches that increased in intensity over 5 days. The patient was transferred to a higher level of care for continuous monitoring.
We discovered that the syringe... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "91%"}, "Analysis": "The email describes that the patient suffered from persistent headaches that increased in intensity over 5 days which is an Adverse Event, requests clinical info... |
SUBJECT: Multi-faceted concern about Product A
BODY:
To whom it may concern,
Our quality team flagged that one blister card contained 9 tablets instead of the stated 10, and the missing tablet was not recovered from the packaging. We have retained samples and photographs for your quality review.
The individual is a 8... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "96%"}, "Analysis": "The email describes that the patient reported dyspnea and chest tightness within 30 minutes of ingestion which is an Adverse Event, requests clinical information... |
SUBJECT: Complex issue involving Product A
BODY:
Dear medical information,
Our quality team observed that the oral syringe provided in the kit had illegible graduation markings making accurate dosing impossible. The receiving pharmacist has completed a detailed inspection report that we can forward upon request.
The ... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "92%"}, "Analysis": "The email reports that the oral syringe provided in the kit had illegible graduation markings making accurate dosing impossible related to Product A which is a Product Complaint, des... |
SUBJECT: Inquiry and feedback about Product A
BODY:
Dear clinical affairs,
Our institution is exploring a narrow network partnership and needs commercial terms in writing.
We need the environmental sustainability report and carbon footprint data for the manufacturing of Product A.
The patient is a 41 year old female... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "93%"}, "Analysis": "The email describes that the patient reported visual disturbances including blurred vision and photophobia after 3 doses which is an Adverse Event, requests clin... |
SUBJECT: Observation during use of Product A
BODY:
Dear patient support,
Our quality team observed that the inhaler canister appeared dented and the counter mechanism was frozen at 0 doses remaining. Our procurement team has placed a hold on further orders from this batch pending resolution.
For our clinical operatio... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "94%"}, "Analysis": "The email requests specific clinical information by asking Can you confirm the shelf life and beyond-use dating for opened vials of Product A? which is Medical Information, rep... |
SUBJECT: Integrated feedback regarding Product A
BODY:
Dear integrated quality and safety team,
The patient is a 36 year old female with generalized anxiety disorder. She noticed significant peripheral edema in both lower limbs after 1 week of use. Emergency management was provided and the event was reported to our in... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "97%"}, "Analysis": "The email reports that the outer box was water-damaged during transit, affecting the legibility of dosage instructions printed on the flap related to Product A which is a Product Com... |
SUBJECT: Request for details about Product A
BODY:
Dear pharmacovigilance team,
Our quality team detected that the child-resistant cap failed to engage properly, raising serious safety problems for household storage. Our pharmacy has flagged this lot and will not dispense until your team investigates.
The individual ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "96%"}, "Analysis": "The email describes that the patient had an episode of syncope approximately 6 hours post-dose which is an Adverse Event, requests clinical information by asking We are... |
SUBJECT: Healthcare provider memo on Product A
BODY:
Dear global safety,
The regional payer consortium has requested additional data to finalize coverage policy.
Is there an institutional contracting program that offers consignment inventory or pay-per-use models for Product A?
The subject is a 38 year old female wi... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "91%"}, "Analysis": "The email reports that the desiccant packet inside the bottle was torn and the contents had spilled over the tablets related to Product A which is a Product Complaint, describes that... |
SUBJECT: Supply and experience review of Product A
BODY:
Dear clinical affairs,
The patient is a 73 year old male with Parkinson disease. He was started on Product A. Over the monitoring period, he had an episode of syncope approximately 6 hours post-dose. We consulted the infectious disease team to rule out secondary... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "96%"}, "Analysis": "The email describes that the patient had an episode of syncope approximately 6 hours post-dose which is an Adverse Event, requests specific clinical information by asking Please cl... |
SUBJECT: Unexpected reaction linked to Product A
BODY:
Dear post-market surveillance,
The patient is a 75 year old male with atrial fibrillation on apixaban. He reported dyspnea and chest tightness within 30 minutes of ingestion. All concomitant medications were reviewed for potential interactions.
We discovered that... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "94%"}, "Analysis": "The email describes that the patient reported dyspnea and chest tightness within 30 minutes of ingestion which is an Adverse Event, requests clinical information... |
SUBJECT: Market access and patient impact of Product A
BODY:
Dear adverse event reporting center,
Our institutional review board has approved a real-world evidence study and we need data sharing agreements for Product A.
We need the global pharmacovigilance contact details and the medical information request portal f... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "95%"}, "Analysis": "The email requests specific clinical information by asking Could you send any recent peer-reviewed publications supporting the efficacy of Product A in patients over 65 years o... |
SUBJECT: Healthcare provider memo on Product A
BODY:
Dear clinical and supply chain team,
The subject is a 67 year old female with breast cancer on adjuvant therapy. She was started on Product A from a batch where the child-resistant cap failed to engage properly, raising serious safety concerns for household storage.... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "91%"}, "Analysis": "The email reports that the child-resistant cap failed to engage properly, raising serious safety concerns for household storage related to Product A which is a Product Complaint, des... |
SUBJECT: Packaging defect and dosing question for Product A
BODY:
Good afternoon,
Our quality team found that the label on the outer carton displayed an incorrect batch number compared to the inner foil strip. Our pharmacy has flagged this lot and will not dispense until your team investigates.
For our clinical opera... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "90%"}, "Analysis": "The email requests specific clinical information by asking Can you share data on the bioavailability of Product A under fed versus fasted conditions? which is Medical Informati... |
SUBJECT: Follow-up needed for Product A
BODY:
Dear compliance team,
Our pharmacy flagged that the solution appeared cloudy with visible particulate matter that was not described in the product leaflet. Our quality officer requests a certificate of analysis for the specific batch in question.
Our integrated delivery n... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "91%"}, "Analysis": "The email requests specific clinical information by asking Our nurses need the preparation instructions, in-compatibility data with common diluents, and any filtration requirem... |
SUBJECT: Supply and experience review of Product A
BODY:
Dear healthcare liaison,
The formulary evaluation subcommittee has requested a comprehensive value dossier ahead of the December meeting.
Could you share the reference pricing in comparable markets and any parallel trade risk assessment for Product A?
To ensur... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "90%"}, "Analysis": "The email requests specific clinical information by asking Can you confirm the shelf life and beyond-use dating for opened vials of Product A? which is Medical Information, rep... |
SUBJECT: Combined quality and clinical report for Product A
BODY:
Dear quality assurance,
Our quality team found that the powder for reconstitution formed clumps that did not dissolve completely after 5 minutes of shaking. The incident has been documented in our internal deviation log and shared with the clinical team... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "92%"}, "Analysis": "The email describes that the patient noticed significant peripheral edema in both lower limbs after 1 week of use which is an Adverse Event, requests clinical informati... |
SUBJECT: Unexpected reaction linked to Product A
BODY:
Dear healthcare liaison,
Our quality team observed that the foil strip was partially cut at an angle, leaving sharp edges that could injure patients during handling. The receiving pharmacist has completed a detailed inspection report that we can forward upon reque... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "98%"}, "Analysis": "The email reports that the foil strip was partially cut at an angle, leaving sharp edges that could injure patients during handling related to Product A which is a Product Complaint,... |
SUBJECT: Pricing inquiry and safety signal for Product A
BODY:
Dear healthcare liaison,
The patient is a 58 year old male with COPD. He developed new-onset atrial fibrillation within 72 hours. The clinical pharmacist performed a comprehensive medication reconciliation.
We discovered that the foil strip was partially ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "93%"}, "Analysis": "The email describes that the individual developed new-onset atrial fibrillation within 72 hours which is an Adverse Event, requests clinical information by askin... |
SUBJECT: Supply and experience review of Product A
BODY:
Dear pharmacovigilance and quality officer,
The managed care contracting team is renegotiating all tier 3 specialty drug arrangements for the upcoming plan year.
Can you share with me the distribution channels or authorized suppliers for Product A?
We need lit... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "98%"}, "Analysis": "The email requests specific clinical information by asking We need literature on efficacy in diabetic populations and details on any glycemic monitoring requirements while on P... |
SUBJECT: Unexpected reaction linked to Product A
BODY:
Dear adverse event reporting center,
Our inspection revealed that the foil strip was partially cut at an angle, leaving sharp edges that could injure patients during handling. We have retained the original shipping container and temperature logger for your investi... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "95%"}, "Analysis": "The email describes that the patient reported dyspnea and chest tightness within 30 minutes of ingestion which is an Adverse Event, requests clinical information by ask... |
SUBJECT: Healthcare provider memo on Product A
BODY:
Dear safety team,
The patient is a 55 year old female with a history of migraine. She noticed significant peripheral edema in both lower limbs after 1 week of use. We initiated corticosteroid therapy and maintained cardiac monitoring.
We discovered that several tab... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "89%"}, "Analysis": "The email describes that the subject noticed significant peripheral edema in both lower limbs after 1 week of use which is an Adverse Event, requests clinical in... |
SUBJECT: Safety and quality note on Product A
BODY:
Dear customer support,
Our quality team observed that the foil strip was partially cut at an angle, leaving sharp edges that could injure individuals during handling. Our procurement team has placed a hold on further orders from this batch pending resolution.
The pa... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "96%"}, "Analysis": "The email describes that the patient developed Stevens-Johnson syndrome-like lesions across torso and arms which is an Adverse Event, requests clinical information by a... |
SUBJECT: Distribution and side-effect profile of Product A
BODY:
Dear compliance team,
We are launching a new specialty pharmacy service line and evaluating high-margin products for inclusion.
Who should we contact from your team for business collaboration or partnership opportunities related to Product A? Are there ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "91%"}, "Analysis": "The email describes that the patient developed Stevens-Johnson syndrome-like lesions across torso and arms which is an Adverse Event, requests clinical informati... |
SUBJECT: Unexpected reaction linked to Product A
BODY:
Good morning,
Our inspection revealed that a vial arrived with a cracked neck, causing leakage of approximately 2 ml of solution. We have segregated the non-conforming material in a locked quarantine area pending your instructions.
The patient is a 38 year old fe... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "90%"}, "Analysis": "The email describes that the patient reported dizziness and orthostatic hypotension after 2 doses which is an Adverse Event, requests clinical information by asking Is ... |
SUBJECT: Urgent concern regarding Product A
BODY:
Dear medical and commercial affairs,
The patient is a 31 year old female with lupus. She was started on Product A. After the first dose she experienced severe nausea and repeated vomiting starting on day 3 of therapy. The dose was held and the patient was monitored ove... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "96%"}, "Analysis": "The email describes that the patient experienced severe nausea and repeated vomiting starting on day 3 of therapy which is an Adverse Event, requests clinical informati... |
SUBJECT: Multi-faceted concern about Product A
BODY:
Dear compliance team,
The patient is a 62 year old female with hypertension and type 2 diabetes. She was started on Product A. During therapy she developed a widespread erythematous rash within 48 hours of the first dose. We consulted the infectious disease team to ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "98%"}, "Analysis": "The email describes that the patient developed a widespread erythematous rash within 48 hours of the first dose which is an Adverse Event, requests clinical information... |
SUBJECT: Comprehensive inquiry on Product A
BODY:
Dear patient support,
The patient is a 47 year old male with major depressive disorder. He was started on Product A. Within days of starting he developed severe photosensitivity with blistering after 14 days of continuous use. The clinical pharmacist performed a compre... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "90%"}, "Analysis": "The email describes that the patient developed severe photosensitivity with blistering after 14 days of continuous use which is an Adverse Event, requests clinical info... |
SUBJECT: Clinical observation with Product A
BODY:
Dear post-market surveillance,
The patient is a 34 year old male previously healthy. He was administered Product A from a lot where one blister card contained 9 tablets instead of the stated 10, and the missing tablet was not recovered from the packaging. We have quar... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "95%"}, "Analysis": "The email describes that the patient developed new-onset atrial fibrillation within 72 hours which is an Adverse Event, requests clinical information by asking Is Produ... |
SUBJECT: Safety and quality note on Product A
BODY:
Dear product team,
The patient is a 41 year old female with asthma and seasonal allergies. She developed a widespread erythematous rash within 48 hours of the first dose. The dose was held and the patient was monitored overnight in the ICU.
We also discovered that t... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "98%"}, "Analysis": "The email describes that the patient developed a widespread erythematous rash within 48 hours of the first dose which is an Adverse Event, requests clinical information... |
SUBJECT: Integrated feedback regarding Product A
BODY:
Good afternoon,
The patient is a 62 year old female with hypertension and type 2 diabetes. She experienced profound fatigue and muscle weakness after 6 days of treatment. Emergency management was provided and the event was described to our internal safety board.
... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "98%"}, "Analysis": "The email reports that a tablet was observed to be split into 2 unequal fragments inside an intact blister cavity related to Product A which is a Product Complaint, describes that th... |
SUBJECT: Follow-up needed for Product A
BODY:
Dear clinical affairs,
As part of our procurement cycle for Q3, we are reassessing supplier agreements for key therapeutic categories.
Is there an institutional contracting program that offers consignment inventory or pay-per-use models for Product A?
To ensure safe pres... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "97%"}, "Analysis": "The email requests specific clinical information by asking Could you clarify the pregnancy category and any teratogenic risk associated with Product A? which is Medical Informa... |
SUBJECT: Clarification sought on Product A
BODY:
Dear pharmacovigilance team,
Our inspection revealed that the solution appeared cloudy with visible particulate matter that was not described in the product leaflet. The receiving pharmacist has completed a detailed inspection report that we can forward upon request.
T... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "90%"}, "Analysis": "The email describes that the patient suffered from insomnia that progressed to near-total sleep deprivation over 1 week which is an Adverse Event, requests clinical inf... |
SUBJECT: Safety and quality note on Product A
BODY:
Dear adverse event reporting center,
Our quality team observed that the desiccant packet inside the bottle was torn and the contents had spilled over the tablets. We have segregated the non-conforming material in a locked quarantine area pending your instructions.
T... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "93%"}, "Analysis": "The email reports that the desiccant packet inside the bottle was torn and the contents had spilled over the tablets related to Product A which is a Product Complaint, describes that... |
SUBJECT: Healthcare provider memo on Product A
BODY:
Dear medical information,
The subject is a 69 year old male with coronary artery disease. He was started on Product A. After the first dose he noticed yellowing of sclera and skin suggestive of hepatic involvement after 10 days. The dose was held and the patient was... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "98%"}, "Analysis": "The email describes that the patient noticed yellowing of sclera and skin suggestive of hepatic involvement after 10 days which is an Adverse Event, requests clinical i... |
SUBJECT: Urgent concern regarding Product A
BODY:
Dear integrated quality and safety team,
The patient is a 26 year old female with epilepsy. She was administered Product A from a lot where the insulin cartridge contained visible fibrils or precipitate that should not have been present. We have retained the original s... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "91%"}, "Analysis": "The email describes that the subject had an anaphylactic reaction with throat swelling and difficulty breathing which is an Adverse Event, requests clinical information... |
SUBJECT: Request for details about Product A
BODY:
Dear pharmacovigilance team,
The managed care contracting team is renegotiating all tier 3 specialty drug arrangements for the upcoming plan year.
Can you confirm the patent expiry date, any pending litigation, and biosimilar readiness timeline for Product A?
Our in... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "97%"}, "Analysis": "The email requests specific clinical information by asking Is Product A approved for pediatric use, and if so, what are the weight-based dosing recommendations? which is Medica... |
SUBJECT: Market access and patient impact of Product A
BODY:
Dear clinical affairs,
The regional payer consortium has requested additional data to finalize coverage policy.
We need the global pharmacovigilance contact details and the medical information request portal for Product A.
Our pharmacy team recently notice... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "93%"}, "Analysis": "The email reports that several tablets were chipped along the edges and had an off-white discoloration inconsistent with the product specification related to Product A which is a Pro... |
SUBJECT: Complex issue involving Product A
BODY:
Dear pharmacovigilance and quality officer,
The patient is a 71 year old male with benign prostatic hyperplasia. He was started on Product A. Within days of starting he noticed dark tarry stools indicating possible gastrointestinal bleeding after 8 days. The patient was... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "93%"}, "Analysis": "The email describes that the individual noticed dark tarry stools indicating possible gastrointestinal bleeding after 8 days which is an Adverse Event, requests clinica... |
SUBJECT: Packaging defect and dosing question for Product A
BODY:
Dear regulatory affairs,
Our pharmacy flagged that the expiration date printed on the bottle was smudged and partially illegible. The receiving pharmacist has completed a detailed inspection report that we can forward upon request.
Our institution is e... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "90%"}, "Analysis": "The email requests specific clinical information by asking Can you share the contraindication list, pregnancy category, and lactation safety data for Product A? which is Medica... |
SUBJECT: Healthcare provider memo on Product A
BODY:
Dear global safety,
The patient is a 73 year old male with Parkinson disease. He noticed significant peripheral edema in both lower limbs after 1 week of use. All concomitant medications were reviewed for potential interactions.
We discovered that a vial arrived wi... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "98%"}, "Analysis": "The email describes that the patient noticed significant peripheral edema in both lower limbs after 1 week of use which is an Adverse Event, requests clinical in... |
SUBJECT: Request for details about Product A
BODY:
Dear medical and commercial affairs,
The patient is a 38 year old female with rheumatoid arthritis. She developed deep-vein thrombosis in the left calf within 2 weeks. All concomitant medications were reviewed for potential interactions.
To guide our ongoing manageme... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "93%"}, "Analysis": "The email describes that the patient developed deep-vein thrombosis in the left calf within 2 weeks which is an Adverse Event, requests specific clinical information by asking Coul... |
SUBJECT: Packaging defect and dosing question for Product A
BODY:
Dear product team,
Our quality team flagged that the ointment tube was severely swollen, suggesting a reaction between the product and the tube lining. Our materials management team requests an immediate supplier corrective action report for this incide... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "96%"}, "Analysis": "The email describes that the patient noticed dark tarry stools indicating possible gastrointestinal bleeding after 8 days which is an Adverse Event, requests cli... |
SUBJECT: Market access and patient impact of Product A
BODY:
Dear product team,
Our institutional review board has approved a real-world evidence study and we need data sharing agreements for Product A.
Can you confirm the lead time and minimum order quantity for direct-to-hospital shipments of Product A?
Our inspec... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "94%"}, "Analysis": "The email describes that the patient had an anaphylactic reaction with throat swelling and difficulty breathing which is an Adverse Event, requests clinical info... |
SUBJECT: Inquiry and feedback about Product A
BODY:
Dear regulatory affairs,
We are launching a new specialty pharmacy service line and evaluating high-margin products for inclusion.
Are there any upcoming label expansions or new indications for Product A that we should factor into our 2025 strategic plan?
The patie... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "98%"}, "Analysis": "The email describes that the individual developed severe photosensitivity with blistering after 14 days of continuous use which is an Adverse Event, requests specific clinical info... |
SUBJECT: Administrative and medical query on Product A
BODY:
Dear regulatory affairs,
Our pharmacy flagged that the child-resistant cap failed to engage properly, raising serious safety concerns for household storage. We have notified the receiving warehouse to inspect all remaining inventory from this shipment.
As p... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "94%"}, "Analysis": "The email requests specific clinical information by asking We require information on the cost-effectiveness model, quality-adjusted life years data, and health technology asses... |
SUBJECT: Labeling error and clinical query about Product A
BODY:
Dear drug safety department,
Our inspection revealed that several tablets were chipped along the edges and had an off-white discoloration inconsistent with the product specification. We have segregated the non-conforming material in a locked quarantine a... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "91%"}, "Analysis": "The email describes that the subject had uncontrolled tremors in both hands beginning the second day which is an Adverse Event, requests clinical information by asking ... |
SUBJECT: Multi-faceted concern about Product A
BODY:
Dear healthcare liaison,
We are preparing a value analysis committee presentation and require supporting materials.
Is there an institutional contracting program that offers consignment inventory or pay-per-use models for Product A?
The individual is a 75 year old... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "96%"}, "Analysis": "The email reports that the aluminum foil backing peeled away too easily, compromising the integrity of individual blisters related to Product A which is a Product Complaint, describe... |
SUBJECT: Clarification sought on Product A
BODY:
Dear medical information,
Our quality team flagged that the desiccant packet inside the bottle was torn and the contents had spilled over the tablets. Please confirm whether a market recall is planned for this batch.
The subject is a 58 year old male with COPD. He had ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "91%"}, "Analysis": "The email describes that the patient suffered from insomnia that progressed to near-total sleep deprivation over 1 week which is an Adverse Event, requests clini... |
SUBJECT: Clarification sought on Product A
BODY:
Dear clinical affairs,
We are transitioning to a centralized distribution model and need to validate new logistics partners for Product A.
Can you confirm the lead time and minimum order quantity for direct-to-hospital shipments of Product A?
To ensure safe prescribin... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "95%"}, "Analysis": "The email requests specific clinical information by asking Please provide the pediatric dosing table, any age-related clearance differences, and the safety data in adolescents ... |
SUBJECT: Combined quality and clinical report for Product A
BODY:
Hello,
The patient is a 78 year old female on chronic warfarin therapy. She experienced profound fatigue and muscle weakness after 6 days of treatment. The clinical team documented the event and scheduled follow-up within 72 hours.
To guide our ongoing... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "93%"}, "Analysis": "The email describes that the patient experienced profound fatigue and muscle weakness after 6 days of treatment which is an Adverse Event, requests specific clinical information by... |
SUBJECT: Issue reported with Product A
BODY:
Hello,
The patient is a 38 year old female with rheumatoid arthritis. She was started on Product A. Over the monitoring period, she encountered a sharp drop in platelet count observed on day 7 lab work. We immediately discontinued the drug and initiated supportive care.
Fo... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "97%"}, "Analysis": "The email describes that the patient experienced a sharp drop in platelet count observed on day 7 lab work which is an Adverse Event, requests specific clinical information by aski... |
SUBJECT: Product quality and adverse experience with Product A
BODY:
Dear patient safety and market access team,
Our quality team observed that one blister card contained 9 tablets instead of the stated 10, and the missing tablet was not recovered from the packaging. Our materials management team requests an immediate... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "98%"}, "Analysis": "The email requests specific clinical information by asking We are seeking the mechanism of action, key clinical trial outcomes, and a comparison with standard of care for Produ... |
SUBJECT: Product quality and adverse experience with Product A
BODY:
Good morning,
Our institutional review board has approved a real-world evidence study and we need data sharing agreements for Product A.
Are there any upcoming label expansions or new indications for Product A that we should factor into our 2025 str... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "93%"}, "Analysis": "The email describes that the patient showed signs of acute renal dysfunction with rising creatinine after 5 days which is an Adverse Event, requests clinical inf... |
SUBJECT: Unexpected reaction linked to Product A
BODY:
Good afternoon,
The patient is a 29 year old male with a history of substance use disorder in remission. He suffered from insomnia that progressed to near-total sleep deprivation over 1 week. We immediately discontinued the drug and initiated supportive care.
We ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "94%"}, "Analysis": "The email describes that the patient suffered from insomnia that progressed to near-total sleep deprivation over 1 week which is an Adverse Event, requests clinical inf... |
SUBJECT: Multi-faceted concern about Product A
BODY:
Dear patient support,
The managed care contracting team is renegotiating all tier 3 specialty drug arrangements for the upcoming plan year.
Can you confirm the patent expiry date, any pending litigation, and biosimilar readiness timeline for Product A?
The patient... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "92%"}, "Analysis": "The email describes that the patient reported dyspnea and chest tightness within 30 minutes of ingestion which is an Adverse Event, requests clinical information... |
SUBJECT: Request for details about Product A
BODY:
Dear integrated quality and safety team,
The pharmacy and therapeutics committee meets next month and we must complete the dossier beforehand.
Is there a patient assistance program or copay support available for outpatient prescriptions of Product A?
Our inspection ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "91%"}, "Analysis": "The email describes that the patient developed deep-vein thrombosis in the left calf within 2 weeks which is an Adverse Event, requests clinical information by a... |
SUBJECT: Follow-up needed for Product A
BODY:
Dear patient safety and market access team,
The patient is a 58 year old male with COPD. He developed Stevens-Johnson syndrome-like lesions across torso and arms. We initiated corticosteroid therapy and maintained cardiac monitoring.
To support evidence-based use of Produ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "96%"}, "Analysis": "The email describes that the patient developed Stevens-Johnson syndrome-like lesions across torso and arms which is an Adverse Event, requests specific clinical information by aski... |
SUBJECT: Market access and subject impact of Product A
BODY:
Hello,
We are launching a new specialty pharmacy service line and evaluating high-margin products for inclusion.
What training resources and educational modules are available for nursing staff administering Product A in an infusion center setting?
The pati... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "95%"}, "Analysis": "The email describes that the patient suffered from insomnia that progressed to near-total sleep deprivation over 1 week which is an Adverse Event, requests clini... |
SUBJECT: Multi-faceted concern about Product A
BODY:
Dear post-market surveillance,
The patient is a 28 year old female, 8 weeks postpartum. She complained of severe abdominal cramping and diarrhea for 3 consecutive days. The dose was held and the patient was monitored overnight in the ICU.
We also discovered that th... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "91%"}, "Analysis": "The email describes that the patient complained of severe abdominal cramping and diarrhea for 3 consecutive days which is an Adverse Event, requests clinical informatio... |
SUBJECT: Follow-up needed for Product A
BODY:
Dear pharmacovigilance team,
Our health system serves approximately 1.2 million lives and we are conducting a quarterly vendor review.
Can you provide the quarterly sales performance data and any regional market share analysis for Product A?
Our incoming inspection revea... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "93%"}, "Analysis": "The email requests specific clinical information by asking What monitoring parameters are recommended during the first 4 weeks of Product A therapy? which is Medical Informatio... |
SUBJECT: Packaging defect and dosing question for Product A
BODY:
Dear pharmacovigilance and quality officer,
Our institution is exploring a narrow network partnership and needs commercial terms in writing.
Our group purchasing organization is aggregating demand across 40 hospitals and needs tiered pricing for Produc... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "98%"}, "Analysis": "The email describes that the patient developed severe photosensitivity with blistering after 14 days of continuous use which is an Adverse Event, requests clinic... |
SUBJECT: Follow-up needed for Product A
BODY:
Good morning,
The patient is a 28 year old female, 8 weeks postpartum. She was started on Product A from a batch where the solution appeared cloudy with visible particulate matter that was not described in the product leaflet. We have retained the original shipping contain... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "96%"}, "Analysis": "The email reports that the solution appeared cloudy with visible particulate matter that was not described in the product leaflet related to Product A which is a Product Complaint, d... |
SUBJECT: Safety and quality note on Product A
BODY:
Dear product team,
We are updating our electronic health system drug database and need standard pricing feeds.
What training resources and educational modules are available for nursing staff administering Product A in an infusion center setting?
Our pharmacy team r... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "90%"}, "Analysis": "The email reports that the insulin cartridge contained visible fibrils or precipitate that should not have been present related to Product A which is a Product Complaint, describes t... |
SUBJECT: Combined quality and clinical report for Product A
BODY:
Dear regulatory affairs,
The subject is a 28 year old female, 8 weeks postpartum. She was administered Product A from a lot where the aluminum foil backing peeled away too easily, compromising the integrity of individual blisters. We have suspended all ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "94%"}, "Analysis": "The email describes that the patient experienced severe nausea and repeated vomiting starting on day 3 of therapy which is an Adverse Event, requests clinical informati... |
SUBJECT: Administrative and medical query on Product A
BODY:
Dear drug safety department,
Our supply chain team noticed delays in recent deliveries and is reviewing alternative distribution models.
We would like to request a formulary dossier that includes budget-impact modeling for Product A in a 500-bed hospital.
... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "91%"}, "Analysis": "The email describes that the patient suffered from insomnia that progressed to near-total sleep deprivation over 1 week which is an Adverse Event, requests specific clinical inform... |
SUBJECT: Inquiry and feedback about Product A
BODY:
Dear healthcare liaison,
The patient is a 26 year old female with epilepsy. She was started on Product A from a batch where the ointment tube was severely swollen, suggesting a reaction between the product and the tube lining. We have retained the original shipping c... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "95%"}, "Analysis": "The email reports that the ointment tube was severely swollen, suggesting a reaction between the product and the tube lining related to Product A which is a Product Complaint, descri... |
SUBJECT: Comprehensive inquiry on Product A
BODY:
Dear pharmacovigilance team,
Our pharmacy flagged that the temperature indicator strip inside the shipping box had turned irreversibly red, indicating cold-chain breach. We have notified the receiving warehouse to inspect all remaining inventory from this shipment.
Ou... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "96%"}, "Analysis": "The email requests specific clinical information by asking Could you provide both the recommended storage conditions and a summary of stability data for Product A under humidit... |
SUBJECT: Distribution and side-effect profile of Product A
BODY:
Dear medical and commercial affairs,
We are launching a new specialty pharmacy service line and evaluating high-margin products for inclusion.
We are preparing a joint-venture proposal and need the licensing terms and territory restrictions for Product ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "92%"}, "Analysis": "The email describes that the patient reported dyspnea and chest tightness within 30 minutes of ingestion which is an Adverse Event, requests clinical information... |
SUBJECT: Combined quality and clinical report for Product A
BODY:
Dear patient support,
The patient is a 31 year old female with lupus. She was started on Product A. Over the monitoring period, she noticed significant peripheral edema in both lower limbs after 1 week of use. The patient was transferred to a higher lev... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "91%"}, "Analysis": "The email describes that the patient noticed significant peripheral edema in both lower limbs after 1 week of use which is an Adverse Event, requests specific clinical information ... |
SUBJECT: Administrative and medical query on Product A
BODY:
Dear drug safety department,
The patient is a 47 year old male with major depressive disorder. He suffered from insomnia that progressed to near-total sleep deprivation over 1 week. The patient was advised to stop the medication and present to the emergency ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "97%"}, "Analysis": "The email describes that the patient suffered from insomnia that progressed to near-total sleep deprivation over 1 week which is an Adverse Event, requests specific clinical inform... |
SUBJECT: Supply and experience review of Product A
BODY:
Dear quality assurance,
We are preparing a value analysis committee presentation and require supporting materials.
Could you share the reference pricing in comparable markets and any parallel trade risk assessment for Product A?
The patient is a 82 year old fe... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "95%"}, "Analysis": "The email describes that the patient developed new-onset atrial fibrillation within 72 hours which is an Adverse Event, requests clinical information by asking O... |
SUBJECT: Request for details about Product A
BODY:
Dear adverse event reporting center,
Our institutional review board has approved a real-world evidence study and we need data sharing agreements for Product A.
We need the environmental sustainability report and carbon footprint data for the manufacturing of Product ... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "90%"}, "Analysis": "The email reports that one blister card contained 9 tablets instead of the stated 10, and the missing tablet was not recovered from the packaging related to Product A which is a Prod... |
SUBJECT: Combined quality and clinical report for Product A
BODY:
Dear regulatory affairs,
We are launching a new specialty pharmacy service line and evaluating high-margin products for inclusion.
Please provide the managed care contract template and any performance-based rebate agreements for Product A.
The patient... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "94%"}, "Analysis": "The email reports that the powder for reconstitution formed clumps that did not dissolve completely after 5 minutes of shaking related to Product A which is a Product Complaint, desc... |
SUBJECT: Comprehensive inquiry on Product A
BODY:
Dear clinical and supply chain team,
The patient is a 36 year old female with generalized anxiety disorder. She experienced severe nausea and repeated vomiting starting on day 3 of therapy. We reduced the dose by 50% but symptoms recurred within 24 hours.
We discovere... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "98%"}, "Analysis": "The email describes that the patient experienced severe nausea and repeated vomiting starting on day 3 of therapy which is an Adverse Event, requests clinical in... |
SUBJECT: Patient feedback concerning Product A
BODY:
Dear pharmacovigilance team,
The individual is a 31 year old female with lupus. She was started on Product A. Within days of starting she encountered profound fatigue and muscle weakness after 6 days of treatment. We consulted the infectious disease team to rule out... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "94%"}, "Analysis": "The email describes that the patient presented with profound fatigue and muscle weakness after 6 days of treatment which is an Adverse Event, requests clinical informat... |
SUBJECT: Follow-up needed for Product A
BODY:
Dear global safety,
The patient is a 38 year old female with rheumatoid arthritis. She was started on Product A. Over the monitoring period, she developed a widespread erythematous rash within 48 hours of the first dose. The dose was held and the patient was monitored over... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "95%"}, "Analysis": "The email describes that the patient developed a widespread erythematous rash within 48 hours of the first dose which is an Adverse Event, requests specific clinical information by... |
SUBJECT: Comprehensive inquiry on Product A
BODY:
Dear drug safety department,
The formulary evaluation subcommittee has requested a comprehensive value dossier ahead of the December meeting.
What is the current wholesale acquisition cost for Product A, and are there volume-based rebates available for hospital system... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "93%"}, "Analysis": "The email requests specific clinical information by asking What is the recommended starting dose for Product A in patients with mild renal impairment? which is Medical Informat... |
SUBJECT: Comprehensive inquiry on Product A
BODY:
Dear drug safety department,
Our quality team observed that the ointment tube was severely swollen, suggesting a reaction between the product and the tube lining. We have retained samples and photographs for your quality review.
The individual is a 29 year old male wi... | {"Classification_of_request": {"Classification": "Product Complaint, Adverse Event, Other", "Confidence_percentage": "93%"}, "Analysis": "The email reports that the ointment tube was severely swollen, suggesting a reaction between the product and the tube lining related to Product A which is a Product Complaint, descri... |
SUBJECT: Pricing inquiry and safety signal for Product A
BODY:
Dear safety team,
The patient is a 28 year old female, 8 weeks postpartum. She was started on Product A. Over the monitoring period, she developed a sharp drop in platelet count observed on day 7 lab work. We administered IV fluids and antihistamines and o... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Other", "Confidence_percentage": "93%"}, "Analysis": "The email describes that the patient experienced a sharp drop in platelet count observed on day 7 lab work which is an Adverse Event, requests specific clinical information by aski... |
SUBJECT: Multi-faceted concern about Product A
BODY:
Dear clinical affairs,
Our quality team observed that the expiration date printed on the bottle was smudged and partially illegible. We have quarantined the affected lot and request a replacement shipment.
The patient is a 29 year old male with a history of substan... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint", "Confidence_percentage": "98%"}, "Analysis": "The email describes that the individual suffered from insomnia that progressed to near-total sleep deprivation over 1 week which is an Adverse Event, requests clinical ... |
SUBJECT: Packaging defect and dosing question for Product A
BODY:
Dear patient safety and market access team,
We are transitioning to a centralized distribution model and need to validate new logistics partners for Product A.
Please provide the schedule for upcoming speaker programs and advisory boards for Product A.... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "94%"}, "Analysis": "The email describes that the patient developed a widespread erythematous rash within 48 hours of the first dose which is an Adverse Event, requests clinical info... |
SUBJECT: Follow-up needed for Product A
BODY:
Hello,
Our health system serves approximately 1.2 million lives and we are conducting a quarterly vendor review.
What is the current wholesale acquisition cost for Product A, and are there volume-based rebates available for hospital systems?
The patient is a 71 year old ... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "89%"}, "Analysis": "The email describes that the individual developed severe photosensitivity with blistering after 14 days of continuous use which is an Adverse Event, requests cli... |
SUBJECT: Administrative and medical query on Product A
BODY:
Dear patient support,
We are updating our electronic health system drug database and need standard pricing feeds.
We are evaluating Product A for our hospital formulary and need the health technology assessment documentation.
Our inspection also revealed t... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "91%"}, "Analysis": "The email describes that the patient suffered from insomnia that progressed to near-total sleep deprivation over 1 week which is an Adverse Event, requests clini... |
SUBJECT: Supply and experience review of Product A
BODY:
Dear drug safety department,
Our quality team observed that a tablet was observed to be split into 2 unequal fragments inside an intact blister cavity. We have notified the receiving warehouse to inspect all remaining inventory from this shipment.
For our clini... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "93%"}, "Analysis": "The email requests specific clinical information by asking Please clarify whether Product A can be crushed or split, and what the bioequivalence data say for the modified-relea... |
SUBJECT: Issue reported with Product A
BODY:
Dear adverse event reporting center,
Our quality team flagged that the child-resistant cap failed to engage properly, raising serious safety concerns for household storage. Our quality officer requests a certificate of analysis for the specific batch in question.
The patie... | {"Classification_of_request": {"Classification": "Adverse Event, Medical Information, Product Complaint, Other", "Confidence_percentage": "94%"}, "Analysis": "The email describes that the patient noticed significant peripheral edema in both lower limbs after 1 week of use which is an Adverse Event, requests clinical in... |
SUBJECT: Observation during use of Product A
BODY:
Dear drug safety department,
Our quality team found that the accompanying patient leaflet was missing entirely from 2 of the 5 cartons delivered. We have retained the original shipping container and temperature logger for your investigation team.
For our clinical ope... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "95%"}, "Analysis": "The email requests specific clinical information by asking Can you supply the posology for hepatic impairment, the dialyzability data, and any dose adjustment for patients on c... |
SUBJECT: Market access and subject impact of Product A
BODY:
Dear product team,
Our quality team observed that the syringe plunger was stuck and could not be depressed smoothly, suggesting a manufacturing defect. Our procurement team has placed a hold on further orders from this batch pending resolution.
For our clin... | {"Classification_of_request": {"Classification": "Medical Information, Product Complaint, Other", "Confidence_percentage": "95%"}, "Analysis": "The email requests specific clinical information by asking Could you provide the maximum recommended daily dose of Product A in adult individuals with normal renal function? wh... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.